logo

For the Inventor, By the Inventor

Berlin, Germany

Epigenomics Ag


USPTO Granted Patents = 68

% Expired Patents = 54.4



Trademarks = 3

Forward Citations = 482

Loading Chart...
Loading Chart...

75 inventors (with patents filed for the assignee):

goldMedal Kurt Berlin (27 out of 27 patents)

silverMedal Reimo Tetzner (18 out of 19 patents)

bronzeMedal Fabian Model (14 out of 14 patents)

4.  Catherine E Lofton-Day (12 out of 12 patents)

5.  Juergen Distler (12 out of 12 patents)

6.  Ralf Lesche (11 out of 12 patents)

7.  Andrew Z Sledziewski (10 out of 10 patents)

8.  Matthias Schuster (10 out of 12 patents)

9.  Alexander Olek (10 out of 12 patents)

10.  Matthias Ballhause (9 out of 9 patents)

11.  Dimo Dietrich (9 out of 12 patents)

12.  Thomas Hildmann (6 out of 7 patents)

13.  Xiaoling Song (6 out of 6 patents)

14.  Jörn Lewin (4 out of 6 patents)

15.  Joern Lewin (4 out of 4 patents)


Core Competencies:
CpG Methylation
Cancer Diagnosis
Cell Proliferative Disorders
Gene Expression
Methylation Patterns
Bisulfite Conversion
DNA Amplification
Prostate Cancer
Breast Cancer
Methylated DNA
Nucleic Acids
PCR Techniques

68 patents:

1. 11345966 - Methods for detecting CpG methylation and for diagnosing cancer (2022-05-31),
2. 11261499 - Methods and nucleic acids for determining the prognosis of a cancer subject (2022-03-01),
3. 11186879 - Methods and nucleic acids for analyses of cellular proliferative disorders (2021-11-30),
4. 10731215 - Method for determining the presence or absence of methylation in a sample (2020-08-04),
5. 10626462 - Methods and nucleic acids for determining the prognosis of a cancer subject (2020-04-21),
6. 10385402 - Methods and nucleic acids for analyses of cellular proliferative disorders (2019-08-20),
7. 9988683 - Method and nucleic acids for the analysis of colon cell proliferative disorders (2018-06-05),
8. 9957575 - Methods for detecting CpG methylation and for diagnosing cancer (2018-05-01),
9. 9939441 - Methods and nucleic acids for analyses for cellular proliferative disorders (2018-04-10),
10. 9868756 - Method for bisulfite treatment (2018-01-16),
11. 9863001 - Method for the detection of cytosine methylations in DNA (2018-01-09),
12. 9850532 - Methods and nucleic acids for the analysis of gene expression associated with the development of prostate cell proliferative disorders (2017-12-26),
13. 9719131 - Method for determining the degree of methylation of defined cytosines in genomic DNA in the sequence context of 5'-CpG-3′ (2017-08-01),
14. 9695478 - Methods and nucleic acids for the analyses of cellular proliferative disorders (2017-07-04),
15. 9670546 - Methods and nucleic acids for analyses of cell proliferative disorders (2017-06-06),
Epigenomics AG is a molecular diagnostics company focused on developing and commercializing innovative products for cancer diagnosis. They specialize in the development and implementation of blood-based tests for early cancer detection, prognosis, and personalized treatment. With a strong focus on epigenetic biomarkers, Epigenomics aims to improve patient outcomes by providing accurate, reliable, and non-invasive diagnostic solutions. For more information, visit their website.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Epigenomics Ag
68 Patents

#19 in D-1000 Berlin

#840 in Germany

#10,868 in the World

Berlin, DE
Berlin, Germany

Epigenomics Ag

Forward Citations = 482

75 inventors:

goldMedal Kurt Berlin (27 out of 27 patents)

silverMedal Reimo Tetzner (18 out of 19 patents)

bronzeMedal Fabian Model (14 out of 14 patents)

4.  Catherine E Lofton-Day (12 out of 12 patents)

5.  Juergen Distler (12 out of 12 patents)

Please report any incorrect information to [email protected]
Loading…